SU1650129A1 - Method for treatment maculodistrophy - Google Patents

Abstract

The invention relates to the field of medicine, namely ophthalmology, and can be used for the treatment of macular dystrophy. The aim of the invention is to increase the visual functions of the eye. The photostimulation of the central zone of the retina is carried out with monochromatic light with a wavelength of 530-590 nm, taking into account the individual spectral sensitivity of the eye in a pulsed mode with a frequency of 25-40 Hz for 10-12 minutes, 10-15 sessions per course of treatment, and lights are held on background retinoprotective antioxidant therapy. The method of treatment allows to increase and stabilize the visual functions in patients with macular dystrophy, is simple to perform and does not have side local and general reactions of the body.

Description

This invention relates to ophthalmology and can be used in the treatment of macular dystrophy.

The purpose of the invention is to increase visual functions.

The method is carried out as follows.

A patient is prescribed a course of antioxidation therapy: direct (tocopherol acetate in capsules in a daily dose of 100 mg, ascorbic acid 0.1–3 times a day) and indirect antioxidants (glutamic acid in tablets in a daily dose of 1.5–2 g , lipoic acid tablets 0,025 g - 3 times a day). The photostimulation is carried out in mesoscopic conditions at an illumination of 30-40 lx after an initial 5-minute adaptation. The photostimulator illuminator is located at a distance of 0.5 m from the patient at eye level. The light window has a diameter of 2.5-3 cm, which corresponds to an angular size of 3-4 ° on the retina. Light pulses of low energy (0.3-0.5 J) from electronic stroboscopes (for example, SS-02) are used, providing illumination at the level of the cornea of 60-100 lux, i.e. 2-3 times higher than background. The frequency of the pulses is determined depending on the critical frequency of the flicker fusion in the patient: for the photostimulation, the frequency of the flickering is used 10-15% below the CFFF.

With a significant difference in the amount of CFFF in both eyes, each eye stimulates photos separately with the corresponding frequency parameters. A pulse frequency of more than 25 Hz is used to irritate the retinal cone apparatus (sticks respond to flicker frequencies below 20 Hz). Taking into account the complex mutual braking effects of the central and peripheral parts of the set

with

oh oh oh

go

ABOUT

The stimulation data and sensitivity data to the radiation spectrum were used for photo-stimulation using monochromatic light with a wavelength of 530–590 nm: 560 with normal spectral sensitivity, 540–10 with a shift in the short-wave side, 580t10 with its displacement towards the long waves. Light monochromatization is achieved by glass absorption narrow-band light filters. The impact of flickering light continues for 10-12 minutes. The patient receives 10-15 sessions per course of treatment.

EXAMPLE 1. B. Sick, 65 years old, was admitted with a diagnosis: Severe sclerotic maculo dystrophy in both eyes. The primary diagnosis of macular dystrophy was established 5 years ago. When entering the visual acuity of the right eye is 0.1, with a correction of +2.5 diopters. 0.3; the left eye - 0,2, with a correction of +2.0 diopters. 0.6. The recovery time of visual acuity after macular illumination is 58 s, on the left - 50 s; The CFFF on the right is 34, on the left is 40. The normal trichromatism is determined on the ananomoscope and Rabkin's tables. In the visual field, small paracentral relative scotomas, more pronounced on the right eye. In the fundus of both eyes, multiple atrophic chorioretinal lesions, mottling, dipigmentation, retinal arteries are narrowed, sclerotic.

The patient received: orally - tocopherol acetate in capsules 100 mg per day, ascorbic acid 0.1 3 times a day, glutamic acid 0.5 0.5 3 times a day, lipoic acid 0.025 g 3 times a day; in both eyes, photostimulation with a monochromatic green light of a wavelength of 560 ± Ynm, in the right eye a flicker frequency of 30 Hz, on the left one - 35 Hz. The photostimulation duration is 10 minutes per eye (with an interval of 2-3 hours), 10 sessions per course of treatment.

As a result of the treatment, visual acuity increased from 0.3 to 0.4 on the right, from 0.6 to 0.7 on the left eye (with correction). The recovery time of visual acuity after macular illumination is 48 s on the right, 35 s on the left. The number of cattle in the field of vision and their size somewhat decreased. The picture of the fundus has not changed.

After 4 months after the treatment, the visual acuity of the right eye is 0.35, the left - 0.7.

Example 2, Boln F., 73 years old, was admitted with a diagnosis: Severe sclerotic macular dystrophy in both eyes. Diagnosis

established a year ago, was treated as an outpatient, received vasodilators, vitamin therapy, tissue therapy. When entering the visual acuity of both eyes -0.3, with a correction of + 2.0-0.65.

The recovery time for visual acuity after macular illumination on the right is 53 s on the left 50 s. In the field of vision of both eyes, no change is detected. CFFF in both eyes is 0 - 45, on the anomaloskop is normal trichromatism with deviation in the direction of protanomaly.

In the fundus of both eyes, in the macular area, mottling, multiple small atrophic chorioretinal foci, redistribution of pigment, retinal arteries of uneven caliber, are sclerotic.

The patient received 15 sessions of photostatus on the background of a complex of antioxidants (inside tocopherol acetate in capsules 100 mg per day, ascorbic acid 0.1–3 p / d, glutamic acid 0.5 g– 3 p / d, lipoic acid, 0.025, 3 times per 5 days (r / d). Flicker frequency 40 Hz, monochromatic orange light wavelength 580 ± 10 nm, photostimulation duration 15 min, 12 sessions per course of treatment. The treatment tolerated well. As a result of the treatment, the visual acuity of both eyes increased to 0.4, with a correction of + 0.2 to 0.8. The recovery time for the severity of vision neither after macular illumination decreased in both eyes to 45 s. Picture 5 of the fundus did not change.

Example 3: Sick M., 70 years old, was admitted with a diagnosis: marked sclerotic macular degeneration of both eyes.

The primary diagnosis of macular dystrophy was established 6 years ago, was repeatedly treated in the hospital, received tissue, vitamin therapy, angioprotectors, parabulbarny and phonophoresis. In spite of the treatment being carried out, condition 5 deteriorated and visual acuity above 0.5 did not rise during the last 2 years.

Upon receipt, the visual acuity of the right eye is 0.4, it is not corrected, the left eye is 0.3, it is not corrected. The recovery time for visual acuity after macular illumination on the right is 62 s, on the left 68 s. KChSM on both eyes is 28, on the anomaloskop is normal trichromatism with deviation in the deuteromal direction. In the fundus 5 in the macular area there are atrophic foci, uneven pigmentation, angiosclerosis.

The patient underwent 12 sessions of photostimulation on the background of antioxidant therapy. Wavelength monochromatic yellow

516501296

Claims (1)

light 540 ± 10 nm, the flicker frequency of 25 Hz, the formula of the invention exposure time 12 min. Visual acuity. The method of treatment of macular dystrophy of pooboi eyes increased to 0.6. Restoration of photostimulation of the retina, distinguishing visual acuity after macular and in order to increase The light in both eyes decreased to 5-function, stimulates 40 s. The state of the refractive media, the eye-central zone of the retina of the monochromatic bottom as at admission. With repeated light with a wavelength of 530-590 nm with nom examination after 3 months visual acuity taking into account the individual spectral sensation of the eyes - 0.6. of the eye in pulsed mode 10 with a frequency of 25-40 Hz. within 10-12 minutes The invention allows significantly 10–15 sessions per course of treatment, and visual functions are stabilized and stabilized lights are performed against the background of a retinol rotoration of the process of antioxidation therapy. 15